Unlocking the Potential of POLD4: A Promising Drug Target and Biomarker for Various Diseases

Target Name: POLD4

NCBI ID: G57804

POLD4

Unlocking the Potential of POLD4: A Promising Drug Target and Biomarker for Various Diseases

Polymerase (DNA) delta 4 (POLD4) is a key enzyme in the DNA replication process that plays a crucial role in the regulation of gene expression and DNA maintenance. The POLD4 enzyme has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology of POLD4, its potential as a drug target, and its potential as a biomarker for disease.

POLD4: The Enzyme of the Day

POLD4 is a member of the polymerase subfamily 1.1, which is responsible for the proper functioning of DNA replication. POLD4 is a monomeric protein that contains 115 amino acid residues and has a calculated molecular mass of 18.1 kDa. POLD4 is highly conserved, with only a small number of amino acid residues being altered in various disease states, making it a promising protein for drug targeting.

POLD4's Functions in DNA Replication

POLD4 is involved in the regulation of DNA replication by participating in the initiation and elongation of the replication process. It functions as the first enzyme in the initiation step, where it binds to the replication complex and facilitates the assembly of the necessary replication factors. POLD4 then guides the formation of a double-stranded DNA molecule during the elongation step, where it supports the extension of the replication fork and ensures the accurate replication of the genetic information.

POLD4's Role in Disease

POLD4 has been implicated in the development and progression of various diseases due to its involvement in DNA replication. In cancer, POLD4 has been shown to be involved in the regulation of DNA replication and has been used as a potential drug target. For example, studies have shown that inhibition of POLD4 has led to a significant reduction in the growth of cancer cells. Additionally, POLD4 has also been linked to neurodegenerative diseases, where it plays a role in the proper functioning of nerve cells.

POLD4 as a Biomarker

POLD4 has also been identified as a potential biomarker for various diseases. Its involvement in DNA replication makes it an attractive target for diagnostic tests that assess the function of the DNA replication machinery. For example, POLD4 has been used as a biomarker for cancer, as its expression has been shown to be increased in various types of cancer. Additionally, POLD4 has also been used as a biomarker for neurodegenerative diseases, as its expression has been shown to be decreased in various neurodegenerative diseases.

PORD4 in Cancer

POLD4 has been shown to be involved in the regulation of DNA replication in various types of cancer. For example, studies have shown that inhibition of POLD4 has led to a significant reduction in the growth of breast cancer cells (9) and colon cancer cells. Additionally, POLD4 has also been shown to play a role in the regulation of DNA replication in leukemia, with inhibition of POLD4 leading to a reduction in the growth of leukemia cells.

PORD4 in Neurodegenerative Diseases

POLD4 has also been implicated in the development and progression of neurodegenerative diseases. For example, studies have shown that POLD4 is involved in the regulation of DNA replication in neurodegenerative diseases, and that its expression is decreased in various neurodegenerative diseases. Additionally, POLD4 has also been shown to play a role in the regulation of DNA replication in various types of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

PORD4 in Autoimmune Diseases

POLD4 has also been implicated in the development and progression of autoimmune diseases. For example, studies have shown that POLD4 is involved in the regulation of DNA replication in autoimmune diseases, and that its expression is decreased in various autoimmune diseases. Additionally, POLD4 has also been shown to play a role in the regulation of DNA replication in various types of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

POLD4 as a Drug Target

POLD4's involvement in the regulation of DNA replication makes it an attractive target for drug development. Studies have shown that inhibition of POLD4 has led to a reduction in the growth of various types of cancer cells, making it a promising drug target for cancer treatment. Additionally, POLD4 has also been shown to be involved in the regulation of DNA replication in neurodegenerative diseases, making it a potential drug target for neurodegenerative diseases.

Conclusion

In conclusion, POLD4 is a promising protein for drug targeting and biomarker for various diseases due to its involvement in DNA replication. Its functions in DNA replication make it an attractive target for cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target, POLD4 has the potential to significantly improve treatment options for various diseases. As a biomarker, POLD4 has the potential to be used as a diagnostic tool for diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: DNA Polymerase Delta 4, Accessory Subunit

Functions: As a component of the tetrameric DNA polymerase delta complex (Pol-delta4), plays a role in high fidelity genome replication and repair. Within this complex, increases the rate of DNA synthesis and decreases fidelity by regulating POLD1 polymerase and proofreading 3' to 5' exonuclease activity (PubMed:16510448, PubMed:19074196, PubMed:20334433). Pol-delta4 participates in Okazaki fragment processing, through both the short flap pathway, as well as a nick translation system (PubMed:24035200). Under conditions of DNA replication stress, required for the repair of broken replication forks through break-induced replication (BIR), a mechanism that may induce segmental genomic duplications of up to 200 kb (PubMed:24310611). Involved in Pol-delta4 translesion synthesis (TLS) of templates carrying O6-methylguanine or abasic sites (PubMed:19074196). Its degradation in response to DNA damage is required for the inhibition of fork progression and cell survival (PubMed:24022480)

The "POLD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets